--- title: "Neuroprotection Peptides | PepTracker Pro" description: "Peptides studied for protecting neural tissue from damage." lang: en json-ld: --- [Skip to main content](#main) **Educational information only.** This site does not provide medical advice. [Read full disclaimer](/disclaimer) [PepTracker Pro](/) [Home](/)[Peptides](/peptides)[Compare](/compare)[Glossary](/glossary)[Blog](/blog)[Calculators](/calculators)[Start Here](/start) [Open the App](https://app.peptrackerpro.com) [Peptides](/peptides)/ Neuroprotection # Neuroprotection Peptides Peptides studied for protecting neural tissue from damage. ### CAQK Medium Evidence A brain-targeting tetrapeptide studied for neuroprotection and targeted drug delivery to injured brain and spinal cord tissue. [Neuroprotection](/benefits/neuroprotection)[brain-health](/benefits/brain-health)[targeted-delivery](/benefits/targeted-delivery)[Inflammation](/benefits/inflammation) [View Details](/peptides/caqk) [\+ Compare](/compare?select=caqk)[](https://app.peptrackerpro.com/?add=caqk) ### Cerebrolysin Medium Evidence A porcine brain-derived peptide mixture approved in some countries for stroke recovery and neurodegenerative conditions. [Neuroprotection](/benefits/neuroprotection)[Cognition](/benefits/cognition)[Recovery](/benefits/recovery) [View Details](/peptides/cerebrolysin) [\+ Compare](/compare?select=cerebrolysin)[](https://app.peptrackerpro.com/?add=cerebrolysin) ### Davunetide Low Evidence An eight-amino-acid ADNP-derived peptide studied for microtubule stabilization, tau-related neuroprotection, and rare ADNP syndrome. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection) [View Details](/peptides/davunetide) [\+ Compare](/compare?select=davunetide)[](https://app.peptrackerpro.com/?add=davunetide) ### Dihexa Low Evidence A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Anti-Aging](/benefits/anti-aging) [View Details](/peptides/dihexa) [\+ Compare](/compare?select=dihexa)[](https://app.peptrackerpro.com/?add=dihexa) ### Humanin Low Evidence An endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians. [Longevity](/benefits/longevity)[Anti-Aging](/benefits/anti-aging)[Neuroprotection](/benefits/neuroprotection)[Metabolism](/benefits/metabolism)+2 more [View Details](/peptides/humanin) [\+ Compare](/compare?select=humanin)[](https://app.peptrackerpro.com/?add=humanin) ### Klotho (Alpha-Klotho) Low Evidence A naturally occurring longevity hormone (secreted alpha-klotho) being studied for cognition and brain aging; a single low-dose injection improved memory in aged monkeys, and a first-in-human Phase 1 trial in older adults is underway. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Anti-Aging](/benefits/anti-aging)[Longevity](/benefits/longevity)+1 more [View Details](/peptides/klotho) [\+ Compare](/compare?select=klotho)[](https://app.peptrackerpro.com/?add=klotho) ### NAD+ Medium Evidence A coenzyme essential for cellular energy production, studied for anti-aging and metabolic support. [Energy](/benefits/energy)[Longevity](/benefits/longevity)[Anti-Aging](/benefits/anti-aging)[Metabolism](/benefits/metabolism)+1 more [View Details](/peptides/nad) [\+ Compare](/compare?select=nad)[](https://app.peptrackerpro.com/?add=nad) ### P21 Medium Evidence An 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[brain-health](/benefits/brain-health)[memory](/benefits/memory) [View Details](/peptides/p21) [\+ Compare](/compare?select=p21)[](https://app.peptrackerpro.com/?add=p21) ### Pinealon Low Evidence A short bioregulatory peptide studied for neuroprotective effects and cognitive support in aging. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Anti-Aging](/benefits/anti-aging)[Longevity](/benefits/longevity) [View Details](/peptides/pinealon) [\+ Compare](/compare?select=pinealon)[](https://app.peptrackerpro.com/?add=pinealon) ### Selank Medium Evidence A synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties. [Anxiety Relief](/benefits/anxiety-relief)[Mood](/benefits/mood)[Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)+1 more [View Details](/peptides/selank) [\+ Compare](/compare?select=selank)[](https://app.peptrackerpro.com/?add=selank) ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. [Weight Management](/benefits/weight-management)[Appetite Regulation](/benefits/appetite-regulation)[Metabolism](/benefits/metabolism)[Fat Loss](/benefits/fat-loss)+3 more [View Details](/peptides/semaglutide) [\+ Compare](/compare?select=semaglutide)[](https://app.peptrackerpro.com/?add=semaglutide) ### Semax Medium Evidence A synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects. [Cognition](/benefits/cognition)[Neuroprotection](/benefits/neuroprotection)[Mood](/benefits/mood)[Recovery](/benefits/recovery) [View Details](/peptides/semax) [\+ Compare](/compare?select=semax)[](https://app.peptrackerpro.com/?add=semax) ### SS-31 High Evidence A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic. [Longevity](/benefits/longevity)[Anti-Aging](/benefits/anti-aging)[Recovery](/benefits/recovery)[Neuroprotection](/benefits/neuroprotection) [View Details](/peptides/ss-31) [\+ Compare](/compare?select=ss-31)[](https://app.peptrackerpro.com/?add=ss-31) ### Trofinetide High Evidence A twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization. [Neuroprotection](/benefits/neuroprotection) [View Details](/peptides/trofinetide) [\+ Compare](/compare?select=trofinetide)[](https://app.peptrackerpro.com/?add=trofinetide) ### Trontinemab Medium Evidence An investigational, brain-penetrant anti-amyloid antibody from Roche/Genentech that uses the proprietary 'Brainshuttle' transferrin-receptor delivery system to reach the brain far more efficiently than conventional antibodies. Trontinemab (development codes RG6102 / RO7126209) is a 2+1 bispecific molecule: it fuses the amyloid-beta-clearing antibody gantenerumab to a fragment that grabs transferrin receptor 1 (TfR1) on blood-brain-barrier cells, hitching a ride into the brain via the same receptor-mediated transport that carries iron. That shuttle lets a low intravenous dose clear amyloid plaques rapidly and deeply while triggering strikingly little of the brain swelling and micro-bleeding (ARIA) that limits approved anti-amyloid drugs. In the Phase Ib/IIa Brainshuttle AD study (NCT04639050), the 3.6 mg/kg dose removed roughly 107 centiloids of amyloid after 28 weeks, driving about 91-92% of participants below the amyloid-positivity threshold (24 centiloids) - with ARIA-E seen in fewer than 5% of participants, well below the ~13% reported for lecanemab and ~24% for donanemab. On the strength of those data, Roche launched two identical pivotal Phase 3 trials - TRONTIER 1 and TRONTIER 2 - in early symptomatic Alzheimer's disease (about 1,600 patients across 18 countries, begun in 2025), and at the 2026 Alzheimer's Association International Conference (AAIC) in London it unveiled PrevenTRON, a Phase 3 prevention trial in 1,600 cognitively unimpaired people at high risk (elevated plasma p-tau217). Trontinemab is a prescription-stage investigational biologic - it is not approved anywhere and is not a supplement or research chemical. [cognitive-health](/benefits/cognitive-health)[Neuroprotection](/benefits/neuroprotection)[amyloid-clearance](/benefits/amyloid-clearance)[alzheimers (investigational)]() [View Details](/peptides/trontinemab) [\+ Compare](/compare?select=trontinemab)[](https://app.peptrackerpro.com/?add=trontinemab) ### VIP Medium Evidence A neuropeptide with broad neuroimmune functions, studied for inflammatory conditions and nerve repair. [Nerve Repair](/benefits/nerve-repair)[Inflammation](/benefits/inflammation)[Immune Support](/benefits/immune-support)[Neuroprotection](/benefits/neuroprotection) [View Details](/peptides/vip) [\+ Compare](/compare?select=vip)[](https://app.peptrackerpro.com/?add=vip) Track Your Research with PepTracker Pro [Try the Free App →](https://app.peptrackerpro.com) [PepTracker Pro](/) Educational peptide information and research tracking tools. Not medical advice. #### Explore - [Peptide Directory](/peptides) - [Compare Peptides](/compare) - [Glossary](/glossary) - [Benefits](/benefits/sleep) #### Learn - [Blog](/blog) - [Calculators](/calculators) - [Start Here](/start) - [About](/about) #### Legal - [Editorial Policy](/editorial-policy) - [Research Disclaimer](/research-disclaimer) - [Disclaimer](/disclaimer) - [Privacy Policy](/privacy) - [Terms of Service](/terms) - [Contact](/contact) © 2026 PepTracker Pro. Educational purposes only. Not medical advice. Always consult a licensed healthcare provider.